Summary: In primary biliary cirrhosis (PBC), clinical events of decompensation are considered indicators of poor prognosis, however, there are limited studies assessing the incidence of decompensating events and the related patient outcomes, which is why researchers conducted this long-term follow-up study. Their findings revealed that in UDCA-treated PBC patients, ascites are usually the first major clinical complication. Prognosis of patients with either ascites, variceal bleeding, or encephalopathy as first complication is associated with a 5-year transplantation-free survival of < 20%. Methods: Long-term follow-up (FU) data of patients treated with ursodeoxycholic acid (UDCA) were derived from 17 North-American and European centers. Res...
OBJECTIVES: The occurrence of decompensation marks a crucial turning point in the course of cirrhosi...
BACKGROUND: Current survival models for primary biliary cirrhosis have limited precision for medium ...
Background and aims: We used data from the Fibrotic Liver Disease (FOLD) Consortium — an established...
OBJECTIVES: In this era of near universal ursodeoxycholic acid (UDCA) treatment for primary biliary ...
OBJECTIVES: In this era of near universal ursodeoxycholic acid (UDCA) treatment for primary biliary ...
Background & Aims: Although ascites is the most frequent first decompensating event in cirrhosis, th...
BACKGROUND/AIMS: One of the prognostic methods for survival in primary biliary cirrhosis (PBC) is th...
Background & Aims: Although several excellent studies have described the natural history of primary ...
Abstract BACKGROUND: The natural history of primary biliary cirrhosis (PBC) is still debated. AIMS:...
OBJECTIVES: The occurrence of decompensation marks a crucial turning point in the course of cirrhosi...
Background & Aims: Patients usually receive a diagnosis of primary biliary cholangitis (PBC) at an e...
Background: Many patients with primary biliary cirrhosis (PBC) are asymptomatic at the time of diagn...
<p><b>Objectives:</b> Liver cirrhosis is characterized by a silent phase until decompensation, which...
Background Current survival models for primary biliary cirrhosis have limited precision for medium a...
BACKGROUND& AIM: Patients usually receive a diagnosis of primary biliary cholangitis (PBC) at an ear...
OBJECTIVES: The occurrence of decompensation marks a crucial turning point in the course of cirrhosi...
BACKGROUND: Current survival models for primary biliary cirrhosis have limited precision for medium ...
Background and aims: We used data from the Fibrotic Liver Disease (FOLD) Consortium — an established...
OBJECTIVES: In this era of near universal ursodeoxycholic acid (UDCA) treatment for primary biliary ...
OBJECTIVES: In this era of near universal ursodeoxycholic acid (UDCA) treatment for primary biliary ...
Background & Aims: Although ascites is the most frequent first decompensating event in cirrhosis, th...
BACKGROUND/AIMS: One of the prognostic methods for survival in primary biliary cirrhosis (PBC) is th...
Background & Aims: Although several excellent studies have described the natural history of primary ...
Abstract BACKGROUND: The natural history of primary biliary cirrhosis (PBC) is still debated. AIMS:...
OBJECTIVES: The occurrence of decompensation marks a crucial turning point in the course of cirrhosi...
Background & Aims: Patients usually receive a diagnosis of primary biliary cholangitis (PBC) at an e...
Background: Many patients with primary biliary cirrhosis (PBC) are asymptomatic at the time of diagn...
<p><b>Objectives:</b> Liver cirrhosis is characterized by a silent phase until decompensation, which...
Background Current survival models for primary biliary cirrhosis have limited precision for medium a...
BACKGROUND& AIM: Patients usually receive a diagnosis of primary biliary cholangitis (PBC) at an ear...
OBJECTIVES: The occurrence of decompensation marks a crucial turning point in the course of cirrhosi...
BACKGROUND: Current survival models for primary biliary cirrhosis have limited precision for medium ...
Background and aims: We used data from the Fibrotic Liver Disease (FOLD) Consortium — an established...